Targeted anti-cancer therapy in the elderly

Wilson Gonsalves, Apar Kishor Ganti

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Cancer is a disease of the elderly with the majority of new diagnoses and deaths from cancer occurring in persons greater than 65 years of age. A major goal of cancer therapy, in the elderly is the preservation of functional independence and quality of life. The advent of targeted therapies has raised the hope that older patients with cancer could be treated as effectively as younger patients and without added toxicities. However, caution must be exercised while addressing the use of these therapies in the elderly population and only after taking into consideration the risks, benefits and prognosis of patients on an individual basis. This article reviews the current literature on the efficacy, cost-effectiveness and toxicity of the currently approved targeted agents in the elderly population.

Original languageEnglish (US)
Pages (from-to)227-242
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume78
Issue number3
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Fingerprint

Neoplasms
Therapeutics
Population
Cost-Benefit Analysis
Quality of Life

Keywords

  • Elderly
  • Monoclonal antibodies
  • Small molecule inhibitors
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Targeted anti-cancer therapy in the elderly. / Gonsalves, Wilson; Ganti, Apar Kishor.

In: Critical Reviews in Oncology/Hematology, Vol. 78, No. 3, 01.06.2011, p. 227-242.

Research output: Contribution to journalReview article

Gonsalves, Wilson ; Ganti, Apar Kishor. / Targeted anti-cancer therapy in the elderly. In: Critical Reviews in Oncology/Hematology. 2011 ; Vol. 78, No. 3. pp. 227-242.
@article{5bfa335be22448199710d1866af863e9,
title = "Targeted anti-cancer therapy in the elderly",
abstract = "Cancer is a disease of the elderly with the majority of new diagnoses and deaths from cancer occurring in persons greater than 65 years of age. A major goal of cancer therapy, in the elderly is the preservation of functional independence and quality of life. The advent of targeted therapies has raised the hope that older patients with cancer could be treated as effectively as younger patients and without added toxicities. However, caution must be exercised while addressing the use of these therapies in the elderly population and only after taking into consideration the risks, benefits and prognosis of patients on an individual basis. This article reviews the current literature on the efficacy, cost-effectiveness and toxicity of the currently approved targeted agents in the elderly population.",
keywords = "Elderly, Monoclonal antibodies, Small molecule inhibitors, Targeted therapy",
author = "Wilson Gonsalves and Ganti, {Apar Kishor}",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.critrevonc.2010.06.001",
language = "English (US)",
volume = "78",
pages = "227--242",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Targeted anti-cancer therapy in the elderly

AU - Gonsalves, Wilson

AU - Ganti, Apar Kishor

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Cancer is a disease of the elderly with the majority of new diagnoses and deaths from cancer occurring in persons greater than 65 years of age. A major goal of cancer therapy, in the elderly is the preservation of functional independence and quality of life. The advent of targeted therapies has raised the hope that older patients with cancer could be treated as effectively as younger patients and without added toxicities. However, caution must be exercised while addressing the use of these therapies in the elderly population and only after taking into consideration the risks, benefits and prognosis of patients on an individual basis. This article reviews the current literature on the efficacy, cost-effectiveness and toxicity of the currently approved targeted agents in the elderly population.

AB - Cancer is a disease of the elderly with the majority of new diagnoses and deaths from cancer occurring in persons greater than 65 years of age. A major goal of cancer therapy, in the elderly is the preservation of functional independence and quality of life. The advent of targeted therapies has raised the hope that older patients with cancer could be treated as effectively as younger patients and without added toxicities. However, caution must be exercised while addressing the use of these therapies in the elderly population and only after taking into consideration the risks, benefits and prognosis of patients on an individual basis. This article reviews the current literature on the efficacy, cost-effectiveness and toxicity of the currently approved targeted agents in the elderly population.

KW - Elderly

KW - Monoclonal antibodies

KW - Small molecule inhibitors

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=79955660925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955660925&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2010.06.001

DO - 10.1016/j.critrevonc.2010.06.001

M3 - Review article

C2 - 20599391

AN - SCOPUS:79955660925

VL - 78

SP - 227

EP - 242

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -